期刊文献+

氯屈膦酸二钠联合化疗缓解多发性骨髓瘤骨痛的疗效观察

原文传递
导出
摘要 目的 评价氯屈膦酸二钠(商品名:固令)对多发性骨髓瘤(MM)患者骨痛的临床疗效.方法 治疗组19例予以氯屈膦酸二钠300 mg/d静脉滴注连续5 d,后予以1600 mg/d口服15 d,每4周重复一次,同时予以MP(美法仑+泼尼松)方案化疗;对照组16例予以MP方案化疗.骨痛缓解作为评价指标.结果 治疗组和对照组用药前均有骨痛,治疗后,治疗组完全缓解6例,部分缓解9例,有效率78.9%;对照组完全缓解2例,部分缓解5例,有效率43.7%.两组患者在用药过程中均未出现严重不良反应,患者耐受良好.结论 氯屈膦酸二钠能有效缓解MM患者骨痛和活动功能障碍,提高患者的生活质量,并能协同化疗促进缓解.
作者 李燕 王晓敏
出处 《白血病.淋巴瘤》 CAS 2008年第2期-,共2页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献6

  • 1Coleman RE,Purohit OP,Vinholes JJ. The future of bisphesphonates in cancer[J].Acta Oncologica,1996,(Z5):23-29.doi:10.3109/02841869609083964.
  • 2Lastulkova I,Adam Z. A questionnaire survey of tolerance and adverse effects of cledronate (Bonefos) in patients with multiple myeloma[J].Vnitrni Lekarstvi,2002,(11):1049-1053.
  • 3张之南.血液病诊断及疗效标准[S]北京:科学出版社,1998228-236349-360385-387396-401.
  • 4赵沄,丛燕,王振荣,沙颖豪,张洪娣,仇霞芬,潘祖玉,胡允平,刘立根.氯屈膦酸二钠联合化疗治疗多发性骨髓瘤的溶骨性病变的疗效观察[J].老年医学与保健,2006,12(1):27-28. 被引量:3
  • 5Derenne S,Amiot M,Barille S. Zoledrenate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment[J].Journal of Bone and Mineral Research,1999,(12):2048-2056.doi:10.1359/jbmr.1999.14.12.2048.
  • 6McCloskey EV,Dunn JA,Kanis JA. Long-term follow-up of a prospective,double-blind,placebo-controlled randomized trial of clodronate in multiple myeloma[J].British Journal of Haematology,2001,(04):1035-1043.doi:10.1046/j.1365-2141.2001.02851.x.

二级参考文献11

  • 1Deschamps M,Baud PR,Coldman AJ,et al.Assessment of adult cancer pain:Shortcomings of current methods.Pain,1998,32:133~134.
  • 2Kyle RA,Jowsey J,Kelly PJ,et al.Multiply myeloma bone disease:the comparative effect of sodium fluoride and calcium carbonate or placebo.N Engl J Med,1975,293:1334~1338.
  • 3Kyle RA.Multiple myeloma:review of 869 cases.Mayo Clin Proc,1975,50:29~40.
  • 4Riccardi A,GrassoB,DanovaM.Bisphophonate in oncology:phsiopathologic bases and clinical avtivity.Tumori,2003,89(3):223~236.
  • 5Coleman RE,Purohit OP.Osteoclast inhibition for the treatment of bone metastases.Cancer Treat Rev,1993,19:79~103.
  • 6Jantunen E.Bisphosphonate therapy in multiple myeloma:past,present,future.Eur J Haematol,2002,69(5-6):257~264.
  • 7Ross JR,Saunders Y,Edmonds PM,et al.A systematic review of the role of bisphophonate in metastatic disease.Health Technol Assess,2004,8(4):1~176.
  • 8Mccloskey EV,Maclenuan IC,Drayson MT,et al.A randomind trail of the effect of clodronate on skeleted monbidity in multiple myeloma.MRC Working Party on leukaemia in adult.Br Haematol,1998,100:317~325.
  • 9Coleman RE,Purohit OP,Vinholes JJ.The future of bisphosphonates in cancer.Acta Oncol,1996,35 (Suppl 5):23~29.
  • 10Heim ME,Clemens MR,Queisser W,et al.Prospective randomized trial of dichloromethyleue bisphosphonate(clodronate) in patients with multiple myeloma requiring treatment:a multicenter study.Onkologie,1995,18:439~448.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部